The latest price target for Insmed (NASDAQ:INSM) was reported by Goldman Sachs on December 15, 2025. The analyst firm set a price target for $258.00 expecting INSM to rise to within 12 months (a possible 29.68% upside). 62 analyst firms have reported ratings in the last year.

The latest analyst rating for Insmed (NASDAQ:INSM) was provided by Goldman Sachs, and Insmed maintained their buy rating.

There is no last upgrade for Insmed

The last downgrade for Insmed Inc happened on August 13, 2025 when Morgan Stanley changed their price target from $112 to $126 for Insmed Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Insmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Insmed was filed on December 15, 2025 so you should expect the next rating to be made available sometime around December 15, 2026.

While ratings are subjective and will change, the latest Insmed (INSM) rating was a maintained with a price target of $225.00 to $258.00. The current price Insmed (INSM) is trading at is $198.96, which is out of the analyst’s predicted range.